Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Biotech is Set for a Blockbuster 2023: Here's Why
11:17am, Friday, 23'rd Dec 2022
The biotech sector has been outperforming the major U.S. indices for the past few months. Can the strength continue?
3 Nasdaq Stocks That Are Up 25% in 3 Months
09:53am, Friday, 23'rd Dec 2022
Should you jump on the bandwagon and buy these surging stocks?
Gilead Sciences Snags FDA Approval For Twice-Yearly HIV Shot
10:55am, Thursday, 22'nd Dec 2022
Gilead won Food and Drug Administration approval for a twice-a-year HIV treatment called Sunlenca on Thursday. The post Gilead Sciences Snags FDA Approval For Twice-Yearly HIV Shot appeared first on I
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?
11:17am, Wednesday, 21'st Dec 2022
Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.
Unusual Options Activity in Apple, Home Depot and 8 Other Stocks
10:47pm, Tuesday, 20'th Dec 2022
Many investors brush off unusual options activity, but others like to “follow the flow.
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data
03:10pm, Tuesday, 20'th Dec 2022
Highlighting the intense competition and sometimes unpredictability of the biopharma space, sector giant Gilead Sciences (NASDAQ: GILD ) stock is down roughly 2% today. While the company's experimenta
Arcus Biosciences, Gilead Sciences shares fall as new lung cancer drug data fails to meet investor expectations
11:51am, Tuesday, 20'th Dec 2022
Arcus Biosciences Inc and Gilead Sciences Inc shares have both taken a tumble after the companies reported positive but not groundbreaking results from a Phase 2 trial involving its new lung cancer dr
Why Is Gilead Sciences Stock Sliding Tuesday? - Gilead Sciences (NASDAQ:GILD)
11:30am, Tuesday, 20'th Dec 2022
Gilead Sciences Inc GILD shares are trading lower Tuesday after the company reported results from its Phase 2 non-small cell lung cancer study.
Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug
08:47am, Tuesday, 20'th Dec 2022
Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that
Gilead: A Phoenix Has Risen From Its Ashes
04:23am, Tuesday, 20'th Dec 2022
Shares of Gilead Sciences recently bounced back to price levels not seen since 2016. During the last decade, the company has transformed itself, and, as a result, Gilead is much more diversified now.
The 7 Best Retirement Stocks to Buy Now
04:34pm, Sunday, 18'th Dec 2022
The best retirement stocks are easy enough to find if you take the time to look. While it still is a challenging time to invest if you have a short time horizon, for investors with longer time horizon
Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology
12:02pm, Monday, 12'th Dec 2022
Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.
Arcellx flies on $325M deal with Gilead's Kite for multiple myeloma treatment
11:42am, Friday, 09'th Dec 2022
Arcellx shares soared in early trade after the clinical-stage biotechnology company announced a global strategic collaboration with Gilead Sciences' Kite to co-develop and co-commercialize its late-st
Gilead to co-develop Arcellx's multiple myeloma drug
08:46am, Friday, 09'th Dec 2022
Gilead Sciences Inc. GILD, +1.91% said Friday that it will co-develop and co-commercialize Arcellx Inc.'s ACLX, +7.22% multiple myeloma treatment candidate, which is currently in Phase 2 clinical tria
Is Gilead Sciences a Buy?
10:00am, Thursday, 08'th Dec 2022
This stock has got something to offer both dividend and growth investors.
